Algorae Pharmaceuticals Advances AI-Driven Drug Discovery with Second Peter MacCallum Cancer Centre Collaboration
Key Insights
Algorae Pharmaceuticals (search) has entered a second collaboration with Peter MacCallum Cancer Centre (search) to validate 24 high-priority drug combinations predicted by its AlgoraeOS version 2 platform across four cancer types.
The AI platform analyzed over 500,000 potential cannabidiol-drug combinations and demonstrated superior performance compared to state-of-the-art models, including those from Google DeepMind (search).
The six-month validation program will use high-throughput screening to test predicted drug synergies in glioblastoma (search), rhabdomyosarcoma (search), melanoma (search), and chronic myelogenous leukemia (search) cell lines.
Algorae Pharmaceuticals (search) (ASX: 1AI) has entered into a second collaboration agreement with the Victorian Centre for Functional Genomics (search) (VCFG) at Peter MacCallum Cancer Centre (search) to validate AI-predicted drug combinations using advanced screening technologies. The partnership represents a critical step in bridging computational drug discovery with biological validation.
AI Platform Demonstrates Superior Performance
The collaboration centers on Algorae's proprietary AlgoraeOS version 2 (AOS2) platform, which has analyzed cannabidiol (CBD) and more than 3,000 approved and investigational drugs across 170 cell lines. This comprehensive analysis represents over 500,000 potential CBD-drug-cell line combinations, providing an unprecedented scope for drug synergy prediction.
According to Algorae's research, the AOS2 platform outperformed representative state-of-the-art models, including those developed by Google DeepMind (search), while demonstrating stronger calibration across biologically-diverse and clinically-relevant synergy regions. The platform's predictions span the full spectrum of drug interactions from strong agonism to strong synergy, providing detailed analysis across four recognized synergy metrics: ZIP, Bliss, HSA, and Loewe.
Systematic Validation Across Multiple Cancer Types
The VCFG will evaluate 24 high-priority drug combinations across four cancer types: glioblastoma (search), rhabdomyosarcoma (search), melanoma (search), and chronic myelogenous leukemia (search). These candidates were selected from an initial pool of 90 potential drug combinations identified through Algorae's preliminary examination in December, which used pre-specified prioritization thresholds balancing predicted synergy magnitude with uncertainty reduction and biological generalizability.
The validation process will include optimizing cell growth conditions for high-throughput drug screening, quantifying treatment effects using microscopy and chemiluminescence assays, generating single-agent dose response curves across all cell lines, and conducting comprehensive synergy screens using selected dose ranges.
Strategic Development Timeline
The project is anticipated to generate key pre-clinical data within six months and could significantly de-risk further development of the identified drug combinations. Dr. James McKenna, Algorae's Chief Scientific Officer, described the agreement as "an important step in the development of AOS2 as we continue to bridge the gap between in silico prediction and biological validation."
The underlying AlgoraeOS platform has been developed in collaboration with the UNSW AI Institute (search) and supported by national research funding. Its latest iteration incorporates measures of uncertainty, enabling more informed decision-making about which candidates should advance to experimental phases.
Clinical and Commercial Implications
Positive validation results could strengthen confidence in the identified drug combinations and create pathways for clinical development, licensing deals, or broader pharmaceutical industry partnerships. The collaboration also positions Algorae to potentially expand its AI platform into new therapeutic areas beyond oncology.
The partnership leverages Peter MacCallum Cancer Centre (search)'s established infrastructure, which treats more than 47,000 patients annually while maintaining a strong research focus. The VCFG, established 16 years ago, has become an internationally-recognized technology platform for advanced high-throughput screens using gene and drug targeting strategies coupled with innovative image analytics.